Cost-Effectiveness Analysis of Certolizumab, Etanercept, Golimumab And Tofacitinib for The Treatment of Moderately To Severely Active Rheumatoid Arthritis
Abstract
Authors
X. Han J.W. Hay
X. Han J.W. Hay
ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now